Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study

The aim of our study was to identify myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute leukemia patients with higher infectious risk during azacitidine treatment. We retrospectively analyzed 298 patients and developed the Azacitidine Infection Risk Model. We selected a subset with high risk for infection (infection rate, 73% vs. 25%) and worse clinical outcome (survival, 8 vs. 29 months) among azacitidine-treated patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - January 21, 2019 Category: Hematology Authors: Krzysztof M ądry, Karol Lis, Przemysław Biecek, Magda Młynarczyk, Jagoda Rytel, Michał Górka, Piotr Kacprzyk, Magdalena Dutka, Marek Rodzaj, Łukasz Bołkun, Dorota Krochmalczyk, Ewa Łątka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Wanda Knopi Tags: Original Study Source Type: research